Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Fletcher

Showing results (1-10 of 112) with videos related to

Pageof 12
Sort By:
Expert Opinion on Therapeutic Patents|October 1, 2019
MCL-1 inhibitors - where are we now (2019)?Steven Fletcher
RSC Medicinal Chemistry|May 19, 2025
Razing the scaffolding: the elimination of non-catalytic functions of kinases through targeted protein degradationSarah Pogash, Steven Fletcher
Future Medicinal Chemistry|November 23, 2013
Recapitulating the α-helix: nonpeptidic, low-molecular-weight ligands for the modulation of helix-mediated protein-protein interactionsMaryanna Lanning, Steven Fletcher
RSC Chemical Biology|February 2, 2026
Protein structural dynamics in covalent drug design: insights from irreversible and reversible covalent inhibitorsRuchira Basu, Steven Fletcher
Expert Opinion on Therapeutic Patents|October 18, 2016
Mcl-1 inhibitors: a patent reviewLijia Chen, Steven Fletcher
British Journal of Pharmacology|March 16, 2026
Targeting protein-protein interactions with reversible covalent modalities: Non-cysteine chemistriesRuchira Basu, Steven Fletcher
Current Topics in Medicinal Chemistry|May 19, 2007
Protein-protein interaction inhibitors: small molecules from screening techniquesSteven Fletcher, Andrew D Hamilton
Bioorganic & Medicinal Chemistry Letters|June 20, 2025
Recent progress in synthetic strategies to develop potent, HDAC8-selective, small-molecule inhibitorsBrandon D Lowe, Steven Fletcher
Biology|September 26, 2015
Multi-Facial, Non-Peptidic α-Helix MimeticsMaryanna E Lanning, Steven Fletcher
RSC Medicinal Chemistry|May 28, 2021
Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6Alexandria M Chan, Steven Fletcher
Pageof 12

Showing results (1-10 of 112) with videos related to

Sort By:
Pageof 12
Expert Opinion on Therapeutic Patents|October 1, 2019
MCL-1 inhibitors - where are we now (2019)?Steven Fletcher
RSC Medicinal Chemistry|May 19, 2025
Razing the scaffolding: the elimination of non-catalytic functions of kinases through targeted protein degradationSarah Pogash, Steven Fletcher
Future Medicinal Chemistry|November 23, 2013
Recapitulating the α-helix: nonpeptidic, low-molecular-weight ligands for the modulation of helix-mediated protein-protein interactionsMaryanna Lanning, Steven Fletcher
RSC Chemical Biology|February 2, 2026
Protein structural dynamics in covalent drug design: insights from irreversible and reversible covalent inhibitorsRuchira Basu, Steven Fletcher
Expert Opinion on Therapeutic Patents|October 18, 2016
Mcl-1 inhibitors: a patent reviewLijia Chen, Steven Fletcher
British Journal of Pharmacology|March 16, 2026
Targeting protein-protein interactions with reversible covalent modalities: Non-cysteine chemistriesRuchira Basu, Steven Fletcher
Current Topics in Medicinal Chemistry|May 19, 2007
Protein-protein interaction inhibitors: small molecules from screening techniquesSteven Fletcher, Andrew D Hamilton
Bioorganic & Medicinal Chemistry Letters|June 20, 2025
Recent progress in synthetic strategies to develop potent, HDAC8-selective, small-molecule inhibitorsBrandon D Lowe, Steven Fletcher
Biology|September 26, 2015
Multi-Facial, Non-Peptidic α-Helix MimeticsMaryanna E Lanning, Steven Fletcher
RSC Medicinal Chemistry|May 28, 2021
Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6Alexandria M Chan, Steven Fletcher
Pageof 12